Literature DB >> 11908740

Prognostic factors in elderly patients with acute myelogenous leukemia: a single center study in Japan.

Yasuhito Nannya1, Yoshinobu Kanda, Kumi Oshima, Makoto Kaneko, Rie Yamamoto, Aki Chizuka, Tamae Hamaki, Miyuki Suguro, Tomohiro Matsuyama, Naoki Takezako, Akiyoshi Miwa, Atsushi Togawa.   

Abstract

We retrospectively analyzed data of 47 patients aged 60 years or older, hospitalized in our institution with the diagnosis of acute myelogenous leukemia (AML), and searched for prognostic factors. Induction with anthracyclines significantly correlated with better complete remission (CR) rate (P = 0.0016) and overall survival (OS) (P < 0.001). Another factor significantly affecting CR rate was higher age (> 70 years) (P = 0.042). Therapy-non-related factors predictive for shorter OS in univariate analyses were age older than 70 years (P = 0.003), percentage of blasts in bone marrow more than 80% (P = 0.048), serum lactate dehydrogenase level higher than 250 U l(-1) (P = 0.032). In stepwise cox proportional hazard regression model, all the four factors predictive for poor OS remained to be independently and significantly prognostic for shorter OS. Only two patients receiving anthracyclines died within 30 days and the frequency was not different from that in patients not receiving anthracyclines. The use of anthracyclines as induction therapy is recommended even in the elderly patients.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11908740     DOI: 10.1080/10428190210204

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN: 1026-8022


  6 in total

1.  Social support and survival in patients with acute myeloid leukaemia.

Authors:  Martin Pinquart; Klaus Höffken; Rainer K Silbereisen; Ulrich Wedding
Journal:  Support Care Cancer       Date:  2006-09-27       Impact factor: 3.603

2.  Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461.

Authors:  Sherif S Farag; Kellie J Archer; Krzysztof Mrózek; Amy S Ruppert; Andrew J Carroll; James W Vardiman; Mark J Pettenati; Maria R Baer; Mazin B Qumsiyeh; Prasad R Koduru; Yi Ning; Robert J Mayer; Richard M Stone; Richard A Larson; Clara D Bloomfield
Journal:  Blood       Date:  2006-03-07       Impact factor: 22.113

3.  Contribution of an aged microenvironment to aging-associated myeloproliferative disease.

Authors:  Virag Vas; Corinna Wandhoff; Karin Dörr; Anja Niebel; Hartmut Geiger
Journal:  PLoS One       Date:  2012-02-21       Impact factor: 3.240

4.  Early prediction of therapy response in patients with acute myeloid leukemia by nucleosomal DNA fragments.

Authors:  Susanne Mueller; Stefan Holdenrieder; Petra Stieber; Torsten Haferlach; Andreas Schalhorn; Jan Braess; Dorothea Nagel; Dietrich Seidel
Journal:  BMC Cancer       Date:  2006-05-30       Impact factor: 4.430

5.  Prognostic factors of survival time after hematopoietic stem cell transplant in acute lymphoblastic leukemia patients: Cox proportional hazard versus accelerated failure time models.

Authors:  Kourosh Sayehmiri; Mohammad R Eshraghian; Kazem Mohammad; Kamran Alimoghaddam; Abbas Rahimi Foroushani; Hojjat Zeraati; Banafsheh Golestan; Ardeshir Ghavamzadeh
Journal:  J Exp Clin Cancer Res       Date:  2008-11-23

6.  Effects of aGVHD and cGVHD on Survival Rate in Patients with Acute Myeloid Leukemia after Allogeneic Stem Cell Transplantation.

Authors:  Shabnam Shokouhi; Sarah Bray; Salar Bakhtiyari; Kourosh Sayehmiri; Kamran Alimoghadam; Ardeshir Ghavamzadeh
Journal:  Int J Hematol Oncol Stem Cell Res       Date:  2015-07-01
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.